Could not find a ticker for this position, may be a filing error
A Dutch health technology company that makes MRI and CT scanners, ventilators, and sleep-care devices used in hospitals and homes. It began in 1891 in Eindhoven, when engineer Gerard Philips and his banker father Frederik started making carbon-filament light bulbs, naming the firm after their family. A fun quirk: until 1912 the Netherlands had no patent law, so the young company freely studied rivals' bulb designs to build its own factory.
Philips Q2 2026: sales up 4%, adjusted EBITA margin 16.4%, outlook raised on US tariff refund
Group sales were EUR 4.4 billion, up 4% on a comparable basis, with growth across all segments.
Show detailsHide details
Adjusted EBITA margin rose to 16.4%, including a US tariff refund benefit of effectively 4.2%.
Income from operations was EUR 609 million, including a EUR 186 million US tariff refund benefit.
Free cash flow was EUR 222 million, including receipt of the US tariff refund.
Full-year 2026 outlook: comparable sales growth reiterated at 3%-4.5%; Adjusted EBITA margin raised to 13.5%-14.0% and free cash flow to EUR 1.5-1.7 billion, reflecting the US tariff refund.
Philips convenes 2026 AGM on May 8, 2026, with board appointments and dividend vote.
Royal Philips announced its Annual General Meeting of Shareholders (AGM) 2026 will be held on May 8, 2026, at Hotel Okura Amsterdam, starting at 10:00 CET.
Show detailsHide details
The agenda includes the appointment of John DeFord as a new Supervisory Board member, effective May 8, 2026.
Proposals to re-appoint Paul Stoffels, Herna Verhagen, and Sanjay Poonen as Supervisory Board members, effective May 8, 2026.
Proposal to re-appoint Roy Jakobs as President/CEO and Chairman of the Board of Management, effective May 8, 2026.
The agenda also includes a proposed Remuneration Policy for the Supervisory Board, the 2025 Remuneration Report (advisory vote), and adoption of financial statements and dividend in cash or shares.